Physician profile
Daniela J Baldi
NPI 1245235399
$4,321.36
in general payments reported to CMS, 2019-2025
26 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $424 · 2021: $376 · 2022: $772 · 2023: $707 · 2024: $835 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,163.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $693.12 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $432.18 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $410.79 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $244.88 | 2019-2024 | |
| Lilly USA, LLC | $204.20 | 2019-2024 | Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $170.45 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $158.42 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $123.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $113.45 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.05 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.07 | 2022-2024 | Jardiance |
| Amgen INC. | $74.27 | 2021-2025 | Krystexxa |
| Amarin Pharma, INC. | $59.40 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $40.46 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.40 | 2019-2021 | |
| Dynavax Technologies Corporation | $32.03 | 2022-2023 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company Ltd. | $31.74 | 2022 | |
| Hikma Pharmaceuticals USA | $27.19 | 2019 | |
| Daiichi Sankyo INC. | $25.96 | 2022 | |
| Abbott Laboratories | $21.75 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $16.58 | 2024 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $14.58 | 2019 | |
| Sanofi Pasteur INC. | $14.05 | 2019 | |
| Eisai INC. | $13.94 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Baldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.